Position in RNA
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$78,816
New position
Shares Held
5,895
first reported quarter
Ownership
0.034%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Derivatives in RNA
reported options exposure · as of Mar 31, 2026CallValue
$0
CallShares
0
PutValue
$668,500
PutShares
50,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026Centiva Capital, LP holds $38,119,877 across 36 Biotechnology names. RNA ranks #31 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
14,610 | $11,288,270 | |
| 2 | ABVX |
Abivax S.A.
|
57,150 | $6,363,652 | |
| 3 | TERN |
Terns Pharmaceuticals, Inc.
|
101,225 | $5,336,582 | |
| 4 | SLNO |
Soleno Therapeutics Inc
|
101,234 | $3,389,314 | |
| 5 | MANE |
Veradermics, Inc
|
20,000 | $1,263,000 | |
| 6 | INBX |
Inhibrx Biosciences, Inc.
|
17,739 | $1,192,592 | |
| 7 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,147 | $958,721 | |
| 8 | CTMX |
CytomX Therapeutics, Inc.
|
200,000 | $940,000 |
All Filings in RNA
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $668,500 | 50,000 | Put | Sole | 2026-05-14 | |
| 2026-03-31 | $78,816 | 5,895 | Shares | Sole | 2026-05-14 | |
| No filing history on record for this holder in this stock. | ||||||